Analyst firms · Morgan Stanley · ARQT

Morgan Stanley ARQT price target and rating history

Arcutis Biotherapeutics Inc. (ARQT) · Health Care

Morgan Stanley rates Arcutis Biotherapeutics Inc. (ARQT) Overweight with a $37 price target, as of its latest action on Mar 2, 2022. It has published 3 rating actions on ARQT since July 2021, including 0 upgrades and 0 downgrades.

Current rating
Overweight
Price target
$37
Median target, all firms
Too few
Actions on ARQT
3

Morgan Stanley price target on ARQT

$50$43$3520222023202420252026
Morgan Stanley price target on ARQT, each point a stated target, July 2021 to March 2022.

Every Morgan Stanley rating on ARQT

Questions about Morgan Stanley and ARQT

What is Morgan Stanley's price target for ARQT?
Morgan Stanley's latest stated price target for Arcutis Biotherapeutics Inc. (ARQT) is $37, from its action on Mar 2, 2022.
What is Morgan Stanley's rating on ARQT?
Morgan Stanley rates ARQT Overweight, a bullish rating, as of Mar 2, 2022.
When did Morgan Stanley last change its view on ARQT?
On Mar 2, 2022, Morgan Stanley raises its price target to $37 from $35, keeps Overweight.

More ARQT rating histories

All Morgan Stanley ratingsARQT news and filingsEvery analyst firm

From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.